Insilico Medicine and SK Biopharmaceuticals have launched a neuroimmune AI drug collaboration that could generate up to $2.5 billion for Insilico. The partners say the program will use Insilico’s Pharma.AI platform—including target validation, generative chemistry, and molecule optimization—while SK contributes development and commercialization capability for resulting candidates. The deal structure reflects a “discover-and-deliver” model: Insilico is expected to take AI-designed assets through preclinical stages, after which SK will steer late-stage development. For SK, the collaboration is aimed at expanding beyond its epilepsy franchise into broader CNS and neuroimmune indications. The reported scope and financial ceiling underscore how large-platform AI players are moving from early research services toward later, monetizable discovery outputs—particularly in areas where complex biology creates demand for faster candidate iteration.